^
Association details:
| Biomarker: | STK11 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Verzenio (abemaciclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine
Excerpt:
PHIAL nominated a KRASA146V mutation, along with alterations in STK11 (identical to other testing) and ATM (Fig. 5A, Supplementary Table 8)...the patient was enrolled in a phase I CDK4 inhibitor (LY2835219) clinical trial based on preclinical data (Level D) implicating a synthetic lethal relationship between activated KRAS and CDK4...The patient achieved stable disease (per RECIST 1.1 criteria; 7.9% reduction in tumor volume compared to baseline) and was on therapy for 16 weeks (Fig. 5B–C).
DOI:
10.1038/nm.3559
